Biography:Bradley J. Monk

From HandWiki
Bradley J. Monk
NationalityAmerican
OccupationGynecologic Oncologist, academician and researcher
AwardsFellow, American Cancer Society of Clinical Oncology
Academic background
EducationB.S., Premedical Zoology
M.D.
Alma materBrigham Young University
University of Arizona College of Medicine – Tucson
Academic work
InstitutionsThe University of Arizona College of Medicine–Phoenix
Creighton University School of Medicine
Dignity Health St. Joseph's Hospital and Medical Center

Bradley J. Monk is an American gynecologic oncologist, academician and researcher. He is a Professor on the Clinical Scholar Track in the Department of Obstetrics and Gynecology at the University of Arizona College of Medicine in Phoenix, Arizona,[1] as well as at the Creighton University School of Medicine in Omaha, Nebraska. He also serves as Director of the Division of Gynecologic Oncology at the St. Joseph's Hospital and Medical Center in Phoenix.[2]

Monk has authored and co-authored over 300 peer reviewed publications, and has focused his research on gynecologic surgery-complex, cervical cancer, ovarian cancer, and other gynecologic cancers. He has received the Ernst Wertheim Award for his research in cervical cancer. Monk is a fellow of the American Society of Clinical Oncology and the Society of Gynecologic Oncology. He is on the board of directors for the GOG Foundation.[3] He is an Associate Editor for Annals of Oncology.[4]

Education

Monk studied at Brigham Young University and received his bachelor's degree in Premedical Zoology in 1982. He graduated from the University of Arizona College of Medicine-Tucson in 1988, and completed his residency in Obstetrics and Gynecology the University of California, Los Angeles in 1992. Between 1988 and 1995, he completed his fellowship in medical genetics at National Institutes of Health (NIH), and in Gynecologic Oncology at M. D. Anderson Cancer Center Houston and the University of California, Irvine.[2]

Career

Upon completing his residency, Monk held appointment as a Clinical Instructor in the Department of Obstetrics and Gynecology at the University of California, before joining Texas Tech University Health Sciences Center in 1995 as an Assistant Professor of Obstetrics and Gynecology and Director of Division of Gynecologic Oncology. From 1997 till 1998, he served there as an assistant professor in the Department of General Surgery. He was then appointed as an Assistant Professor of Obstetrics and Gynecology till 2004, and as a tenured Associate Professor till 2010 at Irvine Medical Center at University of California. Along with this appointment, he held a brief co-appointment at University of Nevada School of Medicine as a Clinical Assistant Professor from 2001 till 2003. He was then appointed as a Professor at Creighton University School of Medicine in 2010,[2] and as Professor in the Department of Obstetrics and Gynecology at University of Arizona College of Medicine in Phoenix in 2012.[1]

Monk held appointment as Gynecologic Oncologist at St. Joseph's Hospital and Medical Center in 2010, and became a Gynecologic Oncologist at Arizona Oncology (US Oncology Network) Biltmore Cancer Center in 2016. He was also appointed by Scottsdale Healthcare and Banner in the Phoenix metropolitan area as a Gynecologic Oncologist.[1]

Research

Monk's research is primarily focused on the prevention and treatment of gynecologic cancers. He was the pioneer to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer[5] and his papers in the New England Journal of Medicine led to the global approval of antiVEGF therapy in recurrent cervical cancer in 2014 and advanced ovarian in 2018. He was also the lead author on the trial of trabectedin in recurrent ovarian cancer.[6]

Cervical cancer

In his study regarding cervical cancer, Monk reviewed several patients which had uterine sarcoma with cervical involvement, a poor response to preoperative radiation, and a poor response to preoperative radiation. Results of his study indicated that radical hysterectomy after radiation is morbid but might be effective in context of treating patients with small recurrent cervical tumors, cervical cancer that responds poorly to radiation, large cervical tumors, patients unable to undergo brachytherapy for cervical cancer, and uterine sarcomas involving the cervix.[7]

Monk also focused his study on the treatment and prevention of cervical cancer and other HPV-associated malignancies using HPV vaccines, and discussed promises and challenges regarding it.[8] In his paper published in 2007, he demonstrated a methodology for examining the impact of HCII testing in terms of the direct cost of cervical cancer cytological screening.[9]

Monk has been the global leader in systemic therapy in cervical cancer. First in 1999, he contributed to the integration of chemotherapy in treating locally advanced disease with radiation.[10] Then, in 2009 Monk defined the systemic therapy standard of care of recurrent cervical cancer being the combination of a platinum medication and paclitaxel (taxane).[11]

He also investigated the usage of targeted therapies in cervical cancer, and evaluated the antiangiogenesis and endothelial growth factor receptor-related treatments.[12] This led to the global approval of the first targeted therapy in gynecologic cancer. The publication in the New England Journal of Medicine (NEJM) of GOG 240 created a new life prolonging standard treatment for persistent, metastatic and recurrent cervical cancer adding bevacizumab to existing options.[13]

In addition to chemotherapy added to radiation, chemotherapy to treat recurrent cervical cancer and the development of bevacizumab, Monk is also a world leader in advancing immune therapy in cervical cancer. He is the steering committee chair and co-first author for EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9.[14] This phase 3 randomized trial compared cemiplimab vs investigator's choice chemotherapy in recurrent/metastatic cervical carcinoma showed a statistically meaningful and clinically relevant improvement in survival. This is the first randomized trial of immune therapy in cervical cancer to meet its primary and secondary endpoints.

In 2020, he together with co-authors, designed the CALLA trial for the purpose of determining the efficacy of the programmed cell death-ligand 1 blocking antibody, durvalumab, with and following concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in women with locally advanced cervical cancer.[15]

Finally, he also conducted a study regarding the usage of sequential chemotherapy in terms of treating early-stage, post–radical hysterectomy cervical cancer.[16] Most recently, Monk has helped develop antibody drug conjugates such as tisotumab vedotin. This new call of agents has great potential to revolutionize the therapeutic landscape.[17]

Ovarian cancer

Monk published a paper in 2005 focused the role of pegylated liposomal doxorubicin in context of ovarian cancer. Results of his study showed the effectiveness of pegylated liposomal doxorubicin in relapsed ovarian cancer and the improved cardiac safety of pegylated liposomal doxorubicin in comparison to conventional anthracyclines.[18] He also conducted a study based on the contributions of 19 genes identified in the literature as increasing the risk of hereditary breast and ovarian cancer (HBOC) in a BRCA1 and BRCA2 negative population of patients with a personal history of breast and/or ovarian cancer by means of a hereditary cancer panel.[19]

The next major accomplishment for Monk in ovarian cancer came in 2010 with the development of trabectedin in recurrent cancer. This novel medication is approved and used extensively around the world.[20] Monk suggested the integration of the tumor genomic profiling with immune profiling in terms of providing a more comprehensive understanding of an individual patient's tumor leading to improved treatment selection and sequencing.[21]

Monk has also been a leader in the field of inhibition of Poly (ADP-ribose) polymerase (PARP) in advanced and recurrent ovarian cancer.[22][circular reference] His pivotal publications in the NEJM have led to global approvals and adoption of Niraparib in recurrent and newly diagnosed advanced ovarian cancer.[23]

Monk was the first in the world to describe the activity of bevacizumab in 2005 to treat recurrent ovarian cancer.[24] He and his colleagues then published many more papers on new targets and the inhibition of antiangiogenesis[25] in ovarian cancer culminating in two NEJM medications and global regulatory approval and adoption.[26][27]

Monk has also focused on rare variants of ovarian cancer such as low-grade serous cancers. His pivotal study of binimetinib showed activity of this MEK inhibitor in a setting of high unmet need.[28] Like ovarian cancer, he is developing immune therapy in ovarian cancer and studies avelumab and nivolumab alone or in combination.

While discussing COVID-19 and ovarian cancer together, Monk explored different alternatives to intravenous (IV) therapies and stated that minimizing patient visits to hospitals and cancer clinics may help mitigate the spread of SARS-CoV-2.[29] Furthermore, he studied the history evidence based on the asbestos and its association with ovarian cancer, while giving reference to WHO's International Agency for Research on Cancer.[30] He also highlighted the application of novel strategies and emerging targets in context of treating the patients with advanced disease.[25]

Quality of life and the patient experience

Monk, along with his colleagues, launched the first study of patient reported outcomes to describe the quality of life in clinical trials with the first report being in 2005.[31] He has been the principal investigator of several quality of life studies to help better define the patient experience and address unmet needs to enhance survivorship.[32]

Awards and honors

  • 1988 – Hewlett-Packard Academic Award
  • 1993 – Fellow, American Cancer Society of Clinical Oncology
  • 2013 – Ernst Wertheim Award, Austrian Association of Gynecologic Oncology[citation needed]

Bibliography

  • Monk, B., Grisham, R., Banerjee, S., Kalbacher, E., Mirza, M., Romero, I., Vuylsteke, P., Coleman, R., Hilpert, F., Oza, A., Westermann, A., Oehler, M., Pignata, S., Aghajanian, C., Colombo, N., Drill, E., Cibula, D., Moore, K., Christy-Bittel, J., Campo, J.M., Berger, R., Marth, C., Sehouli, J., O'malley, D., Churruca, C., Boyd, A., Kristensen, G., Clamp, A., Ray-Coquard, I., & Vergote, I. (2020). MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of Clinical Oncology, 38, 3753 – 3762.
  • Eakin, C., Ewongwo, A., Pendleton, L., Monk, B., & Chase, D. (2020). Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecologic oncology.
  • Oaknin, A., Friedman, C., Roman, L., D'souza, A., Braña, I., Clement-Bidard, F., Goldman, J., Alvarez, E., Boni, V., ElNaggar, A., Passalacqua, R., Do, K., Santin, A., Keyvanjah, K., Xu, F., Eli, L.D., Lalani, A., Bryce, R., Hyman, D., Meric-Bernstam, F., Solit, D., & Monk, B. (2020). Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic oncology.
  • Arend, R., Jackson-Fisher, A., Jacobs, I., Chou, J., & Monk, B. (2021). Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. Cancer Biology & Therapy, 22, 89 – 105.
  • Eakin, C., Ewongwo, A., Pendleton, L., Monk, B., & Chase, D. (2020). Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecologic oncology.

References

  1. ↑ 1.0 1.1 1.2 "Bradley J. Monk, MD". https://arizonaoncology.com/physicians/bradley-j-monk-md-facog-facs/. 
  2. ↑ 2.0 2.1 2.2 "Bradley J. Monk, MD". https://medschool.creighton.edu/faculty-directory-profile/102200/bradley-monk. 
  3. ↑ "GOG Foundation". https://www.gog.org/about/. 
  4. ↑ "Editorial Board – Annals of Oncology – Journal – Elsevier". https://www.journals.elsevier.com/annals-of-oncology/journals.elsevier.com/annals-of-oncology/editorial-board. 
  5. ↑ Monk, B. J.; Minion, L. E.; Coleman, R. L. (2016). "Anti-angiogenic agents in ovarian cancer: past, present, and future". Annals of Oncology 27 (Suppl 1): i33–i39. doi:10.1093/annonc/mdw093. PMID 27141068. 
  6. ↑ Monk, B. J.; Herzog, T. J.; Wang, G.; Triantos, S.; Maul, S.; Knoblauch, R.; McGowan, T.; Shalaby WSW et al. (2020). "A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer". Gynecologic Oncology 156 (3): 535–544. doi:10.1016/j.ygyno.2019.12.043. PMID 31924332. https://pubmed.ncbi.nlm.nih.gov/31924332/. 
  7. ↑ Monk, B. J.; Solh, S.; Johnson, M. T.; Montz, F. J. (1993). "Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcome". European Journal of Gynaecological Oncology 14 (6): 506–511. PMID 8181490. https://pubmed.ncbi.nlm.nih.gov/8181490/. 
  8. ↑ Mahdavi, A.; Monk, B. J. (2005). "Vaccines against human papillomavirus and cervical cancer: promises and challenges". The Oncologist 10 (7): 528–538. doi:10.1634/theoncologist.10-7-528. PMID 16079320. 
  9. ↑ Lonky, N. M.; Hunter, M. I.; Sadeghi, M.; Edwards, G.; Bajamundi, K.; Monk, B. J. (2007). "Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program". Journal of Lower Genital Tract Disease 11 (4): 258–264. doi:10.1097/LGT.0b013e318057f319. PMID 17917570. https://pubmed.ncbi.nlm.nih.gov/17917570/. 
  10. ↑ Peters Wa, 3rd; Liu, P. Y.; Barrett Rj, 2nd; Stock, R. J.; Monk, B. J.; Berek, J. S.; Souhami, L.; Grigsby, P. et al. (2000). "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix". Journal of Clinical Oncology 18 (8): 1606–1613. doi:10.1200/JCO.2000.18.8.1606. PMID 10764420. 
  11. ↑ Monk, B. J.; Sill, M. W.; McMeekin, D. S.; Cohn, D. E.; Ramondetta, L. M.; Boardman, C. H.; Benda, J.; Cella, D. (2009). "Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study". Journal of Clinical Oncology 27 (28): 4649–4655. doi:10.1200/JCO.2009.21.8909. PMID 19720909. 
  12. ↑ Willmott, L. J.; Sumner, D. A.; Monk, B. J. (2010). "Biologics in cervical cancer therapy". Journal of the National Comprehensive Cancer Network 8 (12): 1417–1423. doi:10.6004/jnccn.2010.0105. PMID 21147904. 
  13. ↑ Tewari, Krishnansu S.; Sill, Michael W.; Long, Harry J.; Penson, Richard T.; Huang, Helen; Ramondetta, Lois M.; Landrum, Lisa M.; Oaknin, Ana et al. (2014). "Improved Survival with Bevacizumab in Advanced Cervical Cancer". New England Journal of Medicine 370 (8): 734–743. doi:10.1056/NEJMoa1309748. PMID 24552320. 
  14. ↑ Tewari, Krishnansu Sujata; Vergote, Ignace; Oaknin, Ana; Alvarez, Edwin; Chase, Dana Meredith; Gaillard, Stephanie; Lheureux, Stephanie; Rischin, Danny et al. (2018). "GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.". Journal of Clinical Oncology 36 (15_suppl): TPS5600. doi:10.1200/JCO.2018.36.15_suppl.TPS5600. https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS5600. 
  15. ↑ Mayadev, J.; Nunes, A. T.; Li, M.; Marcovitz, M.; Lanasa, M. C.; Monk, B. J. (2020). "CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study". International Journal of Gynecological Cancer 30 (7): 1065–1070. doi:10.1136/ijgc-2019-001135. PMID 32447296. 
  16. ↑ Randall, Leslie M.; Mayadev, Jyoti; Monk, Bradley J. (March 2021). "Sequential Chemotherapy for Early-Stage, Post–Radical Hysterectomy Cervical CancerAre the STARS Aligned?". JAMA Oncology 7 (3): 353–354. doi:10.1001/jamaoncol.2020.7184. PMID 33443572. https://jamanetwork.com/journals/jamaoncology/article-abstract/2774865. 
  17. ↑ Coleman, Robert L. et al. (May 2021). "Summary". The Lancet Oncology 22 (5): 609–619. doi:10.1016/S1470-2045(21)00056-5. PMID 33845034. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00056-5/fulltext. 
  18. ↑ Thigpen, J. T.; Aghajanian, C. A.; Alberts, D. S.; Campos, S. M.; Gordon, A. N.; Markman, M.; McMeekin, D. S.; Monk, B. J. et al. (2005). "Role of pegylated liposomal doxorubicin in ovarian cancer". Gynecologic Oncology 96 (1): 10–18. doi:10.1016/j.ygyno.2004.09.046. PMID 15589573. https://pubmed.ncbi.nlm.nih.gov/15589573/. 
  19. ↑ Minion, L. E.; Dolinsky, J. S.; Chase, D. M.; Dunlop, C. L.; Chao, E. C.; Monk, B. J. (2015). "Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2". Gynecologic Oncology 137 (1): 86–92. doi:10.1016/j.ygyno.2015.01.537. PMID 25622547. 
  20. ↑ Monk, B. J.; Herzog, T. J.; Kaye, S. B.; Krasner, C. N.; Vermorken, J. B.; Muggia, F. M.; Pujade-Lauraine, E.; Lisyanskaya, A. S. et al. (2010). "Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer". Journal of Clinical Oncology 28 (19): 3107–3114. doi:10.1200/JCO.2009.25.4037. PMID 20516432. 
  21. ↑ Gaillard, Stéphanie L.; Secord, Angeles A.; Monk, Bradley (2016). "The role of immune checkpoint inhibition in the treatment of ovarian cancer". Gynecologic Oncology Research and Practice 3: 11. doi:10.1186/s40661-016-0033-6. PMID 27904752. PMC 5122024. https://gynoncrp.biomedcentral.com/track/pdf/10.1186/s40661-016-0033-6.pdf. 
  22. ↑ "Poly (ADP-ribose) polymerase". September 13, 2022. https://en.wikipedia.org/w/index.php?title=Poly_(ADP-ribose)_polymerase&oldid=1110035610. 
  23. ↑ Mirza, Mansoor R.; Monk, Bradley J.; Herrstedt, Jørn; Oza, Amit M.; Mahner, Sven; Redondo, Andrés; Fabbro, Michel; Ledermann, Jonathan A. et al. (2016). "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer". New England Journal of Medicine 375 (22): 2154–2164. doi:10.1056/NEJMoa1611310. PMID 27717299. https://www.nejm.org/doi/full/10.1056/NEJMoa1611310. 
  24. ↑ Monk, B. J.; Choi, D. C.; Pugmire, G.; Burger, R. A. (2005). "Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer". Gynecologic Oncology 96 (3): 902–905. doi:10.1016/j.ygyno.2004.12.001. PMID 15721449. https://pubmed.ncbi.nlm.nih.gov/15721449/. 
  25. ↑ 25.0 25.1 Arend, R. C.; Jackson-Fisher, A.; Jacobs, I. A.; Chou, J.; Monk, B. J. (2021). "Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease". Cancer Biology & Therapy 22 (2): 89–105. doi:10.1080/15384047.2020.1868937. PMID 33427569. 
  26. ↑ Burger, R. A.; Brady, M. F.; Bookman, M. A.; Fleming, G. F.; Monk, B. J.; Huang, H.; Mannel, R. S.; Homesley, H. D. et al. (2011). "Incorporation of bevacizumab in the primary treatment of ovarian cancer". The New England Journal of Medicine 365 (26): 2473–2483. doi:10.1056/NEJMoa1104390. PMID 22204724. 
  27. ↑ Chan, John K.; Brady, Mark F.; Penson, Richard T.; Huang, Helen; Birrer, Michael J.; Walker, Joan L.; Disilvestro, Paul A.; Rubin, Stephen C. et al. (2016). "Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer". New England Journal of Medicine 374 (8): 738–748. doi:10.1056/NEJMoa1505067. PMID 26933849. 
  28. ↑ Monk, Bradley J.; Grisham, Rachel N.; Banerjee, Susana; Kalbacher, Elsa; Mirza, Mansoor Raza; Romero, Ignacio; Vuylsteke, Peter; Coleman, Robert L. et al. (2020). "MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum". Journal of Clinical Oncology 38 (32): 3753–3762. doi:10.1200/JCO.20.01164. PMID 32822286. 
  29. ↑ Monk, B. J.; Coleman, R. L.; Moore, K. N.; Herzog, T. J.; Secord, A. A.; Matulonis, U. A.; Slomovitz, B. M.; Guntupalli, S. R. et al. (2020). "COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies". Gynecologic Oncology 158 (1): 34–36. doi:10.1016/j.ygyno.2020.04.703. PMID 32370991. 
  30. ↑ Slomovitz, B.; De Haydu, C.; Taub, M.; Coleman, R. L.; Monk, B. J. (2021). "Asbestos and ovarian cancer: examining the historical evidence". International Journal of Gynecological Cancer 31 (1): 122–128. doi:10.1136/ijgc-2020-001672. PMID 33037108. 
  31. ↑ Wenzel, L.; Huang, H. Q.; Monk, B. J.; Rose, P. G.; Cella, D. (2005). "Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study". Journal of Clinical Oncology 23 (24): 5605–5612. doi:10.1200/JCO.2005.08.147. PMID 16110020. 
  32. ↑ Cella, D.; Huang, H. Q.; Monk, B. J.; Wenzel, L.; Benda, J.; McMeekin, D. S.; Cohn, D.; Ramondetta, L. et al. (2010). "Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study". Gynecologic Oncology 119 (3): 531–537. doi:10.1016/j.ygyno.2010.08.020. PMID 20837359. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:Bradley_J._Monk&oldid=3438644"